Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc.
Your view on ELDN
Overview
What the company does, where it operates, and who runs it.
About Eledon Pharmaceuticals, Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David-Alexandre C. Gros
- Headquarters
- 19900 MacArthur Boulevard, Irvine, CA, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- David-Alexandre C. Gros
- Headquarters
- 19900 MacArthur Boulevard, Irvine, CA, US
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant.
Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes.
The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Eledon Pharmaceuticals, Inc., and the rating behind it. ELDN last traded at $2.78; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Eledon Pharmaceuticals, Inc.. Starting points for Eledon Pharmaceuticals, Inc.: EPS -$0.87, beta 0.94 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Eledon Pharmaceuticals, Inc.. Eledon Pharmaceuticals, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Eledon Pharmaceuticals, Inc.. Trailing twelve-month EPS for Eledon Pharmaceuticals, Inc. stands at -$0.87. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Eledon Pharmaceuticals, Inc.. Eledon Pharmaceuticals, Inc. has reported as a listed company since 2014. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Eledon Pharmaceuticals, Inc. valued side by side against its closest peers. Eledon Pharmaceuticals, Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Eledon Pharmaceuticals, Inc., and how their positions are changing. At a $214.6M market value, institutional positions materially move Eledon Pharmaceuticals, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Eledon Pharmaceuticals, Inc. executives and directors. Shares of Eledon Pharmaceuticals, Inc. have traded between $1.43 and $5.08 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Eledon Pharmaceuticals, Inc.. Eledon Pharmaceuticals, Inc. is a $214.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Eledon Pharmaceuticals, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Eledon Pharmaceuticals, Inc.. Coverage tracks Eledon Pharmaceuticals, Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.